- Kentucky city called socialist for buying gas station, undercutting competitor fuel prices
- Israel hits five mosques, sports complex in overnight Gaza strikes
- Hillary Clinton dogged for refusing reporters’ questions on book tour
- EPA tweet baffles: ‘I’m now a C-List celebrity in Kim Kardashian: Hollywood’ iPhone game
- Australian P.M. Abbott: MH17 evidence tampered with on ‘industrial scale’
- Rep. Luis Gutierrez tells Hispanics to vote and ‘punish those’ who oppose amnesty
- Country singer Tim McGraw not sorry for slapping female fan: ‘Things happen’
- Iraq vet cited for owning 14 therapeutic pet ducks
- White House takes credit for drop in unaccompanied children at border
- International crises be damned, Obama’s fundraising trip must go on
Latest Astrazeneca Plc Items
New drugs are making a dent against some hard-to-treat cancers, but some results raise fresh questions about whether the benefit is worth the cost.
A nonprescription version of Nexium, the most popular medicine for frequent, severe heartburn, has just gone on sale.
The board of AstraZeneca on Monday rejected the improved $119 billion takeover offer from U.S. drugmaker Pfizer, a decision that caused a sharp slide in the U.K. company's share price as many investors think it effectively brings an end to the protracted and increasingly bitter takeover saga.
The CEO of drugmaker Pfizer Inc. is telling the governors of Delaware and Maryland that it's premature to speculate about the potential jobs impact of a merger with British rival AstraZeneca PLC.
Maryland's two U.S. senators and four of the state's eight representatives are urging drug maker Pfizer Inc. to make sure that its proposed merger with AstraZeneca PLC doesn't eliminate Maryland jobs.
The governors of Maryland and Delaware are voicing concern about Pfizer Inc.'s efforts to acquire AstraZeneca PLC.
AstraZeneca on Tuesday outlined plans to make sales jump over the next decade, an effort to persuade shareholders the drug maker can do well as an independent company, rather than get bought out by rival Pfizer.
Pharmaceutical giant Pfizer said Friday that it hasn't given up on a deal after British drugmaker AstraZeneca flatly rejected its latest takeover bid, worth $106 billion.
Pfizer Inc. was turned down twice by fellow drugmaker AstraZeneca PLC, but the maker of Viagra and Lipitor said Monday that its proposed $100 billion acquisition makes sense for shareholders of both companies, and it's considering its next steps.